What "Provider Discretion" Means on a GLP-1 Intake — and Why Two Platforms Can Disagree

Same BMI, same history, same honest answers — approved on one platform, declined on another. Neither decision was wrong. Here's the layer of medicine hiding inside that phrase.

Process verified · Updated August 2026

It's one of the most common confusions in GLP-1 telehealth: you complete two intakes with identical information and get two different answers. The decline email cites "provider discretion" and you're left wondering whether you were wrongly rejected — or wrongly approved. Usually, neither. That phrase marks the point where checkbox eligibility ends and actual clinical judgment begins, and platforms genuinely differ in how their judgment is tuned.

The two layers of every intake decision

Layer 1 is the label: BMI ≥30, or ≥27 with a qualifying condition; no absolute contraindications (medullary thyroid cancer history, MEN2, pregnancy). This layer is nearly identical everywhere because it comes from the FDA-approved prescribing criteria. If you clear it, you're eligible — but eligibility is the floor, not the decision.

Layer 2 is the clinician's risk judgment, applied to everything else you disclosed: the gallbladder history, the eating-disorder history, the borderline medication interaction, the GI condition, the two prior pancreatitis workups that came back clean. None of these is an automatic no on the label. Each is a judgment call — and this is where a licensed human, not an algorithm, is legally required to decide whether prescribing to you is appropriate care.

Why platforms land differently on the same patient

• Clinical policies differ by design. Every platform gives its clinicians internal guidelines — which histories require records review, which require a synchronous video visit, which are declined outright. A conservative platform declines what a moderate one escalates to video. Both are practicing defensible medicine; they've just drawn the caution line in different places.
• The individual clinician matters. Within any platform, discretion is personal — that's what the word means. Two physicians can weigh the same borderline history differently, exactly as they would in two different offices in the same city.
• Asynchronous review sees less. A questionnaire-only platform has only your words; one that requires video can ask follow-ups and approve cases a form-only reviewer wouldn't touch. More interaction generally means more nuance.
• Risk posture is a business reality too. Platforms under regulatory scrutiny, or those burned by adverse events, tune conservative. That's not cynicism — it's how medical organizations everywhere respond to risk.

What to do after a decline

1. Read the reason if one is given. "Discretion" plus a named concern (a medication, a condition) tells you what to address or document.
2. Don't re-apply with edited answers. Beyond the honesty problem, you'd be removing exactly the information a prescriber needs — the medication interacts with your real history, not your edited one.
3. Escalate the format instead. A platform with synchronous video visits, or a pay-per-visit clinician who can review records and talk it through, can appropriately approve cases an async form cannot.
4. Borderline or complex history? Your PCP or an obesity-medicine specialist is the setting built for it — and telehealth can still handle the ongoing refills afterward.

Platforms suited to a real conversation

If your case has nuance, pick intake formats with more bandwidth. Found's process spans brand and compounded pathways with human navigation for complicated situations:

YourEra pairs its intake with licensed clinicians and ongoing support rather than a one-shot form decision:

The bottom line

"Provider discretion" is the system working: a licensed clinician personally deciding whether remote prescribing fits your specific history. Different platforms tune that judgment differently, so a decline at one is routing information, not a verdict — take the borderline case to a format with more eyes on it.